Tocilizumab in patients infected by SARS-CoV2

dc.contributor.author	Sancho, Milagros
dc.contributor.author	Muñiz, Javier
dc.contributor.author	Cardinal_Fernández, Pablo
dc.date.accessioned	2022-03-07T13:16:33Z
dc.date.issued	2021-03-19
dc.identifier.citation	Sancho M, Muñiz J, Cardinal-Fernández P. Tocilizumab in patients infected by SARS-CoV2. Med Clin (Eng Ed). 2021;156(8):402-406	es_ES
dc.identifier.issn	2387-0206
dc.identifier.uri	http://hdl.handle.net/2183/29890
dc.language.iso	eng	es_ES
dc.publisher	Elsevier	es_ES
dc.relation.uri	https://doi.org/10.1016/j.medcle.2020.12.010	es_ES
dc.rights	Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International Licence (CC-BY-NC-ND 4.0)	es_ES
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.title	Tocilizumab in patients infected by SARS-CoV2	es_ES
dc.title.alternative	Tocilizumab en el paciente con COVID-19	es_ES
dc.type	info:eu-repo/semantics/article	es_ES
dc.rights.access	info:eu-repo/semantics/embargoedAccess	es_ES
dc.date.embargoEndDate	2022-03-19	es_ES
dc.date.embargoLift	2022-03-19
UDC.journalTitle	Medicina Clínica (English Edition)	es_ES
UDC.volume	156	es_ES
UDC.issue	8	es_ES
UDC.startPage	402	es_ES
UDC.endPage	406	es_ES